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Abstract
Although data from several studies support the use of arginine vasopressin (AVP) for the treatment of hypotension
concomitant with pulmonary hypertension (PH) in the cardiac surgery setting, to our knowledge, no previous studies
have reported the effect of AVP on the systemic and pulmonary circulation of patients with PH secondary to lung
diseases. In this report, we present the hemodynamic responses to bolus administrations of AVP and noradrenaline
in a patient with PH secondary to pulmonary emphysema. The patient showed low systemic vascular resistance
hypotension during off-pump single-lung transplantation. The bolus administration of AVP (0.5 U) increased systemic
arterial pressure by 35.2%, with a minimal change in pulmonary arterial pressure, resulting in a significant decrease in
the pulmonary arterial pressure/systemic arterial pressure ratio. In contrast, the bolus administration of noradrenaline
(10 or 20 μg) increased both systemic and pulmonary arterial pressures by 14.8 and 6.7%, respectively. In summary, the
bolus administration of AVP effectively increased systemic arterial pressure with a minimal effect on pulmonary arterial
pressure in a patient with PH secondary to pulmonary emphysema. This case highlights the potential utility of AVP to
treat low systemic vascular resistance hypotension in patients with PH secondary to lung diseases.
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Background
Surgery and anesthesia pose a significant risk for patients
with pulmonary hypertension (PH) [1–3]; therefore,
perioperative management of these patients presents a
major challenge to physicians. Several studies in patients
undergoing cardiac surgery have demonstrated that argin-
ine vasopressin (AVP) can effectively ameliorate systemic
hypotension without increasing pulmonary vascular resist-
ance [4–6]. These results support the administration of
AVP for the treatment of hypotension concomitant with
PH in the cardiac surgery setting. However, to our know-
ledge, no previous studies have reported the effect of AVP
on the systemic and pulmonary circulation of patients with
PH secondary to lung diseases. In this report, we present
the hemodynamic responses to bolus administrations of
AVP and noradrenaline (NAD) in a patient with PH
secondary to pulmonary emphysema. The patient showed
low systemic vascular resistance hypotension during off-
pump single-lung transplantation. We discuss the challenge
of managing intraoperative hypotension in a patient with
PH, with focus on the choice of vasopressor in this setting.
Case presentation
A 61-year-old man (174 cm, 56 kg) with pulmonary
emphysema and secondary PH underwent off-pump,
single-right-lung transplantation from a brain-dead donor.
His preoperative status was Hugh–Jones class IV (unable to
walk more than about 50 m without rest), and arterial
blood gas analysis at admission showed a PaO2 of 74.9 mm
Hg and a PaCO2 of 35.3 mm Hg at an inhalation rate of
1 L/min O2. A preoperative transthoracic echocardiogram
* Correspondence: mizota@kuhp.kyoto-u.ac.jp
Department of Anesthesia, Kyoto University Hospital, 54
Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto 606-8507, Japan
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Mizota et al. JA Clinical Reports  (2017) 3:1 
DOI 10.1186/s40981-016-0072-3
showed normal left ventricular systolic function (ejection
fraction, 60%) and PH with an estimated systolic pulmonary
arterial pressure (PAP) of 66 mm Hg. Symptoms of right
heart failure, such as lower-limb edema, were not present.
Written informed consent was obtained from the patient
for the publication of this case report.
The anesthetic chart, with a focus on hemodynamic pa-
rameters and vasoactive drugs, is presented in Fig. 1. Upon
entering the operating room, standard monitoring devices,
including an electrocardiograph and a pulse oximeter, were
attached to the patient, and a peripheral venous catheter
was inserted. In addition, an arterial catheter was inserted
into the right radial artery. Anesthesia was induced with
midazolam (2 mg), propofol (60 mg), and fentanyl (250 μg)
and maintained with sevoflurane (0.8–1%) and remifentanil
(0.05–1 μg/kg/min). A pulmonary arterial catheter was
inserted after induction of anesthesia and intubation. Initial
pulmonary artery catheter readings revealed moderate PH,
as indicated by a systemic arterial pressure (SAP) and PAP
of 87/52 and 52/28 mm Hg, respectively. Inhalation of
nitric oxide (10–20 ppm) along with continuous infusion of
milrinone (0.25–0.5 μg/kg/min) and prostaglandin E1
(0.01 μg/kg/min) was initiated, but neither SAP nor PAP
changed significantly in response to the administration of
these drugs. After the right pulmonary artery was clamped,
systolic PAP increased to 60–70 mm Hg.
The patient exhibited low systemic vascular resistance
hypotension (systemic vascular resistance, 280–520 dyne
s cm−5; systolic SAP, 70–90 mm Hg) during the surgery.
Therefore, continuous infusion of dopamine (2–3 μg/kg/
min), NAD (0.1–0.2 μg/kg/min), and AVP (2 U/h) was
administered to maintain SAP. In addition, bolus adminis-
trations of NAD (10 or 20 μg, administered 15 times) or
AVP (0.5 U, administered twice) were used from the time
of clamping of the pulmonary artery until initiation of
reperfusion. The intervals between bolus administrations
of NAD and AVP ranged from 3 to 12 min. The patient’s
cardiac index remained high (4.1–7.6 L/min/m2) through-
out the operation.
Figure 2 shows the patient’s hemodynamic responses to
bolus doses of NAD and AVP administered from the time
of clamping of the pulmonary artery until reperfusion. The
bolus administration of NAD increased systolic SAP by
14.8% relative to that immediately before administration; in
addition, it increased systolic PAP by 6.7% relative to
pretreatment values (Fig. 2a, c). The bolus administration of
AVP also increased systolic SAP by 35.2%; however, it
affected PAP only minimally, resulting in a significant
decrease in the PAP/SAP ratio from 0.87 to 0.65 (Fig. 2b, d).
Systolic PAP decreased with reperfusion and remained in
the range of 40–50 mm Hg thereafter. Systolic SAP also de-
creased after reperfusion and several bolus doses of NAD
were required, although this stabilized within about 40 min.
The transplanted lung had adequate perfusion and oxygen-
ation. The operating time was 358 min and the total vol-
ume of blood loss was 613 mL; no blood transfusion was
required. The postoperative course was largely uneventful,
except for a tracheostomy, which was performed on post-
operative day 2, owing to pulmonary edema in the trans-
planted lung. The patient was weaned from the ventilator
on postoperative day 8 and from inotropic support on post-
operative day 10. The patient was discharged from the hos-
pital 10 weeks after surgery.
Discussion
Here, we present a case of off-pump single-lung trans-
plantation for pulmonary emphysema concomitant with
secondary PH, in which the bolus administration of AVP
effectively increased SAP with a minimal effect on PAP.
Maintaining adequate SAP is especially important in pa-
tients with PH, because systemic hypotension decreases
coronary perfusion pressure, thereby causing myocardial
ischemia and right heart failure [7, 8]. The ideal vasopres-
sor agent for patients with PH should increase systemic
vascular resistance with a minimal effect on pulmonary
vascular resistance and improve the contractility of the
right ventricle; however, most vasopressors used in clinical
anesthesia and intensive care for the augmentation of
systemic vascular resistance will also increase pulmonary
vascular resistance [9]. For example, sympathomimetic
vasopressors, such as NAD, exert their systemic vasopres-
sor effects through α1-adrenoceptor agonism, which also
causes pulmonary vasoconstriction and may potentially
impair right ventricular function [10]. In fact,
Fig. 1 Anesthetic chart. Double circle marks represent start/end of
surgery; cross marks represent start/end of anesthesia; a triangle
mark represents endtracheal intubation
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noradrenaline caused elevation of PAP in our patient, al-
though to a lesser degree than that of SAP.
AVP is a nonsympathomimetic vasopressor, which causes
vasoconstriction via activation of the V1 vasopressin receptor
[11]. In vitro and in vivo studies have demonstrated that AVP
produces systemic vasoconstriction with relatively fewer
effects on the pulmonary circulation; such combined effects
produce a desirable decrease in the pulmonary vascular re-
sistance/systemic vascular resistance ratio [12–14]. This
AVP-mediated selective vasoconstriction of the systemic ves-
sels has also been shown in several clinical studies in patients
undergoing cardiac surgery [4–6]. However, the pathological
mechanisms of PH in patients who undergo cardiac surgery
are different from those in patients with PH secondary to
lung diseases. PH in cardiac surgery patients is commonly
caused by elevated pulmonary venous pressure, whereas that
secondary to lung diseases is caused by alterations in lung
structure or function [15]. To date, data on the effect of AVP
on systemic and pulmonary circulation in patients with PH
secondary to lung diseases are lacking. In our patient, the
bolus administration of AVP selectively increased SAP, which
seems to reflect selective vasoconstriction of the systemic
vessels. This phenomenon suggests that patients with PH
secondary to lung diseases also benefit from the administra-
tion of AVP for the treatment of systemic hypotension.
The data presented in this report should be interpreted
cautiously. Although the authors analyzed the hemodynamic
responses to bolus administrations of AVP and NAD, con-
tinuous infusion of these drugs might have different effects.
In addition, several drugs, including AVP and NAD, that
have influence on systemic and pulmonary vascular
resistance were continuously administered during the sur-
gery. Although the administration flow rate of these drugs
was constant in most of the period from the time of
clamping of the pulmonary artery until reperfusion, continu-
ous infusion of these drugs might have affected the observed
hemodynamic responses.
Although AVP is not indicated for treatment of hypoten-
sion in Japan, AVP was used without the approval of the
Ethics Committee in this case because it was an emergent
Fig. 2 Hemodynamic responses to bolus doses of NAD and AVP. a, b Representative responses of blood pressure to bolus doses of NAD (a) and AVP
(b). c, d Changes in blood pressure before and after bolus doses of NAD (c) and AVP (d). Blood pressure (PAP or SAP) just before the administration of
NAD or AVP was considered the baseline level. The peak blood pressures within 3 min after the administration of NAD or AVP were obtained.
Horizontal lines represent mean values. NAD noradrenaline, AVP arginine vasopressin, PAP pulmonary arterial pressure, SAP systemic arterial pressure
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situation in which hypotension persisted despite the
administration of NAD and we did not have time to wait
for Ethics Committee approval. However, AVP use in
vasodilatory shock has been shown to be safe in many
studies [16] and was approved in 2014 by the Food and
Drug Administration [17]. We consider that AVP use in
this case was not ethically problematic.
The potential risks associated with the administration of
AVP should be carefully considered. AVP may cause myo-
cardial dysfunction probably owing to direct myocardial
effects, including coronary vasoconstriction [18]. Cardiac
function should be closely monitored using a pulmonary
artery catheter or transesophageal echocardiography during
the administration of AVP.
Conclusions
The authors observed a 35.2% increase in SAP with a min-
imal change in PAP, resulting in a significant decrease in
the PAP/SAP ratio after the bolus administration of AVP
in a patient with PH secondary to pulmonary emphysema.
This case highlights the potential utility of AVP to treat
low systemic vascular resistance hypotension in patients
with PH secondary to lung diseases.
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